Annexin A5 at low doses prevents atherosclerosis - Study published in Atherosclerosis
(Thomson Reuters ONE) -
Solna, Sweden, March 2nd, 2012 -Treatment with low doses of recombinant Annexin
A5 prevents vascular remodelling in a preclinical study. These results were
recently published in an article in Atherosclerosis.
Patients who undergo common surgery for cardiovascular disease are at risk for
inflammation-driven complications after the intervention. It has previously been
shown that Annexin A5 beneficially affects remodelling in a preclinical model of
coronary bypass grafting.
This study showed that Annexin A5 could prevent injury induced accelerated
atherosclerosis and thickening of the vascular intima, in a model mimicking
catheter-based percutaneous interventions (PCI) in mice. The results confirm
that the anti-inflammatory effect of recombinant Annexin A5 could be seen in
doses 3-10 times lower than previously investigated. PCI has become a gold
standard in rapidly treating patients with acute heart attack. Millions of PCI
procedures are done per year due to acute coronary syndrome (ACS) and the number
is rapidly increasing.
"These recently published findings support our approach to develop recombinant
Annexin A5 as an anti-inflammatory therapy, primarily targeting prevention of
complications following vascular surgery. We have successfully developed a cost-
effective manufacturing process which has been transferred to the cGMP facility
and we are now actively discussing co-development opportunities for further
preclinical and clinical studies", says Carina Schmidt, CEO of Athera.
About Athera Biotechnologies AB (publ)
Athera has a unique and in-depth understanding of the immunological components
in atherosclerosis, the inflammatory process leading to cardiovascular disease
(CVD). The company currently has two biopharmaceutical product candidates aimed
at treating patients with cardiovascular conditions and a biomarker linked to
the therapeutic approach.
Athera's vision is to develop recombinant Annexin A5 for prevention of
complications in patients with peripheral artery disease (PAD) undergoing
vascular surgery. The project is currently in preclinical phase.
PC-mAb from Athera is in late preclinical development, using a unique fully
human monoclonal antibody. PC-mAb is being developed to restore cardio-
protective levels of anti-PC and prevent secondary CVD events after acute
coronary syndrome. In addition, Athera has developed a biomarker and companion
diagnostic CVDefine® kit. The biomarker, anti-PC, is linked to increased risk
for cardiovascular disease and could in the future be used for identification of
patients that benefit from Athera's novel therapeutics.
Athera, a Swedish company, is part of the Karolinska Development AB (publ)
portfolio. www.athera.se
For further Information:
Athera Biotechnologies AB (publ)
Chief Executive Officer
Carina Schmidt
Tel +46 761938190
c.schmidt(at)athera.se
News Release as PDF:
http://hugin.info/143298/R/1590919/499879.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Athera Biotechnologies AB via Thomson Reuters ONE
[HUG#1590919]
Unternehmensinformation / Kurzprofil:
Datum: 02.03.2012 - 14:01 Uhr
Sprache: Deutsch
News-ID 121118
Anzahl Zeichen: 3946
contact information:
Town:
Solna
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 164 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Annexin A5 at low doses prevents atherosclerosis - Study published in Atherosclerosis"
steht unter der journalistisch-redaktionellen Verantwortung von
Athera Biotechnologies AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
